Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002
Salmeterol, added to usual therapy, is an effective bronchodilator over 12 months of treatment in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002
Evaluation of tiotropium rotacaps once daily in patients with chronic obstructive pulmonary disease over 4 weeks Source: Eur Respir J 2005; 26: Suppl. 49, 289s Year: 2005
Efficacy of azithromycin vs. ciprofloxacin in the treatment of patients with acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 544s Year: 2002
Efficacy of erdosteine (E) in the treatment of exacerbated and stable chronic bronchitis or chronic obstructive pulmonary disease (CB/COPD): a meta-analysis of individual patient data Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Source: Eur Respir J 2002; 19: 928-935 Year: 2002
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001
A 6 week study of the efficacy and safety of UK-500,001 dry powder for inhalation (DPI) in adults with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2007 - New insights into the treatment of COPD Year: 2007
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 146s Year: 2001
Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002
Correlation between eradication of infecting organism on days 3-5 of antibiotic therapy and clinical cure in patients with acute exacerbations of chronic bronchitis (AECB) Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 74-81 Year: 2003
A comparison of the effects of lung function between low dose theophylline and oral β2-agonist in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 215s Year: 2006
The efficacy and treatment length of oral corticosteroids in patient with acute exacerbation of chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 295s Year: 2005
How frequent is bronchodilator reversibility in patients with stable asthma bronchiale and chronic obstructive lung disease (COPD) receiving maintenance therapy? Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012
Formoterol demonstrates bronchodilator efficacy in patients with reversible or poorly reversible chronic obstructive pulmonary disease (COPD), regardless of concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 177s Year: 2001
Single dose budesonide/carmoterol fixed combination improves lung function over 24 hours in patients with moderate to severe persistent asthma Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Formoterol (Modulite), tiotropium and their combination in patients with acute exacerbation of chronic bronchitis: preliminary data Source: Eur Respir J 2005; 26: Suppl. 49, 285s Year: 2005
The influence of inhalation device for bronchodilators on the results of therapy in primary care patients with bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Asthma control or asthma severity Year: 2008
Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001